Castle Biosciences
Biotechnology Research • 
Friendswood, Texas, United States • 501-1000 Employees
Company overview
| Headquarters | 505 S Friendswood Dr, Suite 401, Friendswood, Texas 77546, US |
| Phone number | +18667889007 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Skin Cancer, Melanoma, Next Gen Sequencing, Cutaneous Melanoma, Diagnostic Cancer Testing, Uveal Melanoma, Barrett'S Esophagus, Cutaneous Squamous Cell Carcinoma, Dermatologic Cancer, Esophageal Adenocarcinoma, Gene Expression Profile Tests |
| Founded | 2008 |
| Employees | 501-1000 |
| Socials |
Key Contacts at Castle Biosciences
Stacey Gilbert
Director, Payer Policy Compliance And Reimbursement Strategy
John Cheneval
Executive Director, Business Development
Lj Delponte
Sales Director Gi East At Castle Biosciences - Tissuecypher For Barrett’S Esophagus
Kim Caple
Member Board Of Directors
Jason Musgrove
National Sales Director
Armineh Kajoian
Medical Director
Alyson Durke
Regional Business Director, South
Tanya Nanda
Product Owner Ii - Tech Cspo
Brian Faley
Senior Medical Science Liaison Director - East
Lisa Demiro Tuoto
Regional Business Director
Castle Biosciences Email Formats
Castle Biosciences uses 2 email formats. The most common is {first name}{last name} (e.g., johndoe@castlebiosciences.com), used 86.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@castlebiosciences.com | 86.6% |
{first initial}{last name} | jdoe@castlebiosciences.com | 12.3% |
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. The Company’s innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. Castle currently markets five proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, Barrett’s esophagus, and uveal melanoma. DecisionDx®-Melanoma, Castle’s test for invasive cutaneous melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. DecisionDx®-SCC is the Company’s GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. MyPath® Melanoma provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. TissueCypher® Barrett’s Esophagus is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus. DecisionDx®-UM, the standard of care in uveal melanoma staging, is Castle's GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. Castle Biosciences is based in Friendswood, TX, (a suburb of Houston) and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.
Castle Biosciences revenue & valuation
| Annual revenue | $346,300,000 |
| Revenue per employee | $552,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,108,100,000 |
| Total funding | $266,800,000 |
Employees by Management Level
Total employees: 501-1000
Seniority
Employees
Employees by Department
Castle Biosciences has 263 employees across 17 departments.
Departments
Number of employees
Castle Biosciences Tech Stack
Discover the technologies and tools that power Castle Biosciences's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Marketing automation
Analytics
Programming languages
Advertising
Analytics
UI frameworks
Analytics
JavaScript libraries
CRM
Tag managers
Reverse proxies
Brazil
Belgium
United Kingdom
Qatar
Frequently asked questions
4.8
40,000 users
